Search research articles
Contact Us
Filters
Showing results (1-10 of 56) with videos related to
Page
of 6
Sort By:
JAMA
|
January 13, 1989
Representation of American blacks in clinical trials of new drugs
C K Svensson
The Journal of Pharmacy and Pharmacology
|
October 1, 1987
Relationship between antipyrine elimination rate constant, clearance and volume of distribution in the rat
C K Svensson
Clinical Pharmacokinetics
|
October 1, 1989
Ethical considerations in the conduct of clinical pharmacokinetic studies
C K Svensson
Journal of Pharmaceutical Sciences
|
October 1, 1986
Effect of the immunomodulator tilorone on antipyrine disposition in the rat
C K Svensson
Clinical Pharmacology and Therapeutics
|
October 1, 1988
Is blood sampling for determination of antipyrine pharmacokinetics in healthy volunteers ethically justified?
C K Svensson
Clinical Pharmacokinetics
|
January 1, 1987
Clinical pharmacokinetics of nicotine
C K Svensson
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 1, 1994
Evidence that the biotransformation of dapsone and monoacetyldapsone to their respective hydroxylamine metabolites in rat liver microsomes is mediated by cytochrome P450 2C6/2C11 and 3A1
C Vage, C K Svensson
Research Communications in Chemical Pathology and Pharmacology
|
February 1, 1994
Glucocorticoid induction of hepatic acetyl CoA:arylamine N-acetyltransferase activity in the rat
H Zaher, C K Svensson
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
January 1, 1992
Effect of H2-receptor antagonists on rat liver cytosolic acetyl CoA:arylamine N-acetyltransferase activity
C K Svensson, M Tomilo
Biochemical Pharmacology
|
June 28, 1996
Arylacetamide deacetylase activity towards monoacetyldapsone. Species comparison, factors that influence activity, and comparison with 2-acetylaminofluorene and p-nitrophenyl acetate hydrolysis
C V Preuss, C K Svensson
Page
of 6
Search research articles
Search
Showing results (1-10 of 56) with videos related to
Sort By:
Page
of 6
JAMA
|
January 13, 1989
Representation of American blacks in clinical trials of new drugs
C K Svensson
The Journal of Pharmacy and Pharmacology
|
October 1, 1987
Relationship between antipyrine elimination rate constant, clearance and volume of distribution in the rat
C K Svensson
Clinical Pharmacokinetics
|
October 1, 1989
Ethical considerations in the conduct of clinical pharmacokinetic studies
C K Svensson
Journal of Pharmaceutical Sciences
|
October 1, 1986
Effect of the immunomodulator tilorone on antipyrine disposition in the rat
C K Svensson
Clinical Pharmacology and Therapeutics
|
October 1, 1988
Is blood sampling for determination of antipyrine pharmacokinetics in healthy volunteers ethically justified?
C K Svensson
Clinical Pharmacokinetics
|
January 1, 1987
Clinical pharmacokinetics of nicotine
C K Svensson
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 1, 1994
Evidence that the biotransformation of dapsone and monoacetyldapsone to their respective hydroxylamine metabolites in rat liver microsomes is mediated by cytochrome P450 2C6/2C11 and 3A1
C Vage, C K Svensson
Research Communications in Chemical Pathology and Pharmacology
|
February 1, 1994
Glucocorticoid induction of hepatic acetyl CoA:arylamine N-acetyltransferase activity in the rat
H Zaher, C K Svensson
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
January 1, 1992
Effect of H2-receptor antagonists on rat liver cytosolic acetyl CoA:arylamine N-acetyltransferase activity
C K Svensson, M Tomilo
Biochemical Pharmacology
|
June 28, 1996
Arylacetamide deacetylase activity towards monoacetyldapsone. Species comparison, factors that influence activity, and comparison with 2-acetylaminofluorene and p-nitrophenyl acetate hydrolysis
C V Preuss, C K Svensson
Page
of 6